BCR-ABL kinase dynamics in drug resistance.

被引：0
|
作者：
Azam, M
Nardi, V
Shakespeare, W
Latek, RR
Bohacek, R
Veach, D
Clarkson, B
Sawyer, TK
Daley, GQ
机构：
[1] Childrens Hosp, Boston, MA 02115 USA
[2] Ariad Pharmaceut, Cambridge, MA USA
[3] Whitehead Inst, Cambridge, MA 02142 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9021S / 9022S
页数：2
相关论文
共 50 条
  • [41] BCR-ABL regulates phosphatidylinositol 3-kinase-p110γ transcription and activation and is required for proliferation and drug resistance
    Hickey, FB
    Cotter, TG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (05) : 2441 - 2450
  • [42] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [43] Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors
    Li, Shaoguang
    Li, Dongguang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2007, 11 (06) : 1251 - 1262
  • [44] Biology of BCR-ABL
    Chopra, R
    Pu, QQ
    Elefanty, AG
    BLOOD REVIEWS, 1999, 13 (04) : 211 - 229
  • [45] Interaction of the Bcr-Abl tyrosine kinase with the Src-kinase Hck
    Stanglmaier, M
    Kleinlein, I
    Warmuth, M
    Reis, S
    Konieczny, A
    Hallek, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S46 - S46
  • [46] An alternative Abl-kinase inhibitor overcomes imatinib resistance in cells expressing mutant forms of Bcr-Abl
    von Bubnoff, N
    Peschel, C
    Duyster, J
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 (40) : 2100 - 2103
  • [47] Charting the molecular network of the drug target Bcr-Abl
    Brehme, Marc
    Hantschel, Oliver
    Colinge, Jacques
    Kaupe, Ines
    Planyavsky, Melanie
    Koecher, Thomas
    Mechtler, Karl
    Bennett, Keiryn L.
    Superti-Furga, Giulio
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (18) : 7414 - 7419
  • [48] Inhibition of Bcr-Abl kinase activity with imatinib induces poly (ADP) ribosylation in Bcr-Abl positive hematopoietic cells.
    Moehring, A
    van der Kuip, H
    Wohlbold, L
    Duyster, J
    Aulitzky, WE
    BLOOD, 2003, 102 (11) : 202B - 202B
  • [49] Resistance to STI: is bcr-abl gene itself involved ?
    Mahon, FX
    M S-MEDECINE SCIENCES, 2001, 17 (11): : 1192 - 1193
  • [50] Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias
    Katsoulas, A
    Rachid, Z
    Brahimi, F
    McNamee, J
    Jean-Claude, BJ
    LEUKEMIA RESEARCH, 2005, 29 (06) : 693 - 700
12345